Democratic Takeover of House Sparks Drug-Price Legislation Talks: But Strong Legislation Unlikely Given Patient and Industry Opposition.

摘要

HHS has proposed regulations to attack high drug prices, a priority for the current administration. Both parties have spoken out against the drug companies but the change in control of the House is no guarantee of pricing legislation moving forward. And if drug manufacturers, PBMs, and others are adamant about tackling drug prices, why do they oppose the best cost-cutting proposals?